Exane Derivatives’s Antares Pharma, Inc. ATRS Stock Holding History

Exane Derivatives’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-104	Closed	-$426	–	1063
2022 Q1	$426	Sell	104 -11,386	-99%	-$41.3K	﹤0.01%	885
2021 Q4	$41K	Sell	11,490 -24,895	-68%	-$87.1K	0.01%	517
2021 Q3	$132K	Buy	36,385 +2,139	+6%	+$8.65K	0.03%	488
2021 Q2	$150K	Buy	+34,246	New	+$140K	0.03%	479
2021 Q1	–	Sell	-1,613	Closed	-$6.44K	–	977
2020 Q4	$6.44K	Hold	1,613	–	–	﹤0.01%	545
2020 Q3	$4.36K	Sell	1,613 -29,881	-95%	-$82.7K	﹤0.01%	516
2020 Q2	$86.6K	Sell	31,494 -317	-1%	-$884	0.02%	313
2020 Q1	$75.1K	Buy	+31,811	New	+$108K	0.02%	318

Other funds holding ATRS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Exane Derivatives's ATRS Position: Q2 2022 in Review

Exane Derivatives sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 104 shares — an estimated $426 sold.

Exane Derivatives first reported a position in ATRS in Q1 2020 and held it in 8 quarters. The position peaked at $150K in Q2 2021. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.

Exane Derivatives reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 104 Antares Pharma, Inc. shares in Q2 2022, an estimated $426.
Exane Derivatives first reported a position in Antares Pharma, Inc. in Q1 2020 and held it in 8 quarters.
Exane Derivatives's Antares Pharma, Inc. position peaked at $150K in Q2 2021.
1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.